Literature DB >> 28735124

Inherent Tumor Characteristics That Limit Effective and Safe Resection of Giant Nonfunctioning Pituitary Adenomas.

Hiroshi Nishioka1, Takayuki Hara2, Yuichi Nagata3, Noriaki Fukuhara3, Mitsuo Yamaguchi-Okada3, Shozo Yamada4.   

Abstract

BACKGROUND: Surgical treatment of giant pituitary adenomas is sometimes challenging. We present our surgical series of giant nonfunctioning adenomas to shed light on the limitations of effective and safe tumor resection.
METHODS: The preoperative tumor characteristics, surgical approaches, outcome, and histology of giant nonfunctioning adenoma (>40 mm) in 128 consecutive surgical patients are reviewed. The follow-up period ranged from 19 to 113 months (mean 62.2 months).
RESULTS: A transsphenoidal approach was used in the treatment of 109 patients and a combined transsphenoidal transcranial approach in 19 patients. A total of 93 patients (72.7%) underwent total resection or subtotal resection apart from the cavernous sinus (CS). The degree of tumor resection, excluding the marked CS invasion, was lower in tumors that were larger (P = 0.0107), showed massive intracranial extension (P = 0.0352), and had an irregular configuration (P = 0.0016). Permanent surgical complications developed in 28 patients (22.0%). Long-term tumor control was achieved in all patients by single surgery, including 43 patients with adjuvant radiotherapy. Most tumors were histologically benign, with a low MIB-1 index (<3.0%) beside a few tumors mainly silent adenomas of pituitary-specific transcription factor lineage.
CONCLUSIONS: Irrespective of the surgical approach, massive intracranial extension, an irregular configuration, and marked CS invasion are inherent factors that independently limit effective resection. These high-risk tumors require an individualized therapeutic strategy.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Combined approach; Giant; Intracranial extension index; Nonfunctioning; Pituitary adenoma; Transsphenoidal surgery

Mesh:

Year:  2017        PMID: 28735124     DOI: 10.1016/j.wneu.2017.07.043

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  9 in total

1.  Microscopic Transsphenoidal Resection of Giant Pituitary Adenomas: Analysis of the Factors Limiting the Degree of Resection in 73 Cases.

Authors:  Zhijie Pei; Jiaxing Wang; Shuwen Mu; Tianshun Feng; Meina Wang; Shentong Yu; Liangfeng Wei; Yi Fang; Shousen Wang
Journal:  Front Neurol       Date:  2022-05-27       Impact factor: 4.086

Review 2.  Giant pituitary adenoma: histological types, clinical features and therapeutic approaches.

Authors:  Pedro Iglesias; Víctor Rodríguez Berrocal; Juan José Díez
Journal:  Endocrine       Date:  2018-06-16       Impact factor: 3.633

3.  Transcranial approach as surgical treatment for giant pituitary adenoma during COVID 19 pandemic - What can we learn?: A case report.

Authors:  Nyoman Golden; Wayan Niryana; Steven Awyono; Putu Eka Mardhika; Made Bhuwana Putra; Made Stefanus Biondi
Journal:  Interdiscip Neurosurg       Date:  2021-02-25

4.  Transventricular Preforniceal Approach Combined with Endoscopic Transnasal Surgery for a Giant Pituitary Adenoma: A Case Report and Literature Review.

Authors:  Tomohiro Matsumoto; Takahiro Ono; Tomo Onodera; Masaya Oda; Masataka Takahashi; Tomoya Omae; Hiroaki Shimizu
Journal:  NMC Case Rep J       Date:  2021-12-22

5.  Outcome of giant pituitary tumors requiring surgery.

Authors:  Stephan Gaillard; Sosthène Adeniran; Chiara Villa; Anne Jouinot; Marie-Laure Raffin-Sanson; Loic Feuvret; Pierre Verrelle; Fidéline Bonnet; Anthony Dohan; Jérôme Bertherat; Guillaume Assié; Bertrand Baussart
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-29       Impact factor: 6.055

6.  Surgical management of giant pituitary neuroendocrine tumors: Meta-analysis and consensus statement on behalf of the EANS skull base section.

Authors:  Giulia Cossu; Emmanuel Jouanneau; Luigi M Cavallo; Sebastien Froelich; Daniele Starnoni; Lorenzo Giammattei; Ethan Harel; Diego Mazzatenta; Micheal Bruneau; Torstein R Meling; Moncef Berhouma; Ari G Chacko; Jan F Cornelius; Dimitrios Paraskevopoulos; Henry W S Schroeder; Idoya Zazpe; Romain Manet; Paul A Gardner; Henry Dufour; Paolo Cappabianca; Roy T Daniel; Mahmoud Messerer
Journal:  Brain Spine       Date:  2022-03-28

7.  The role of multimodal navigation in endoscopic endonasal surgery for giant pituitary adenomas.

Authors:  Chen Yang; Jiarui Zhang; Jianzhong Li; Nan Wu; Dong Jia
Journal:  Gland Surg       Date:  2019-12

8.  Solid tumor size for prediction of recurrence in large and giant non-functioning pituitary adenomas.

Authors:  Ching-Chung Ko; Chin-Hong Chang; Tai-Yuan Chen; Sher-Wei Lim; Te-Chang Wu; Jeon-Hor Chen; Yu-Ting Kuo
Journal:  Neurosurg Rev       Date:  2021-10-04       Impact factor: 3.042

9.  Identification of the Extradural and Intradural Extension of Pituitary Adenomas to the Suprasellar Region: Classification, Surgical Strategies, and Outcomes.

Authors:  YouQing Yang; YouYuan Bao; ShenHao Xie; Bin Tang; Xiao Wu; Le Yang; Jie Wu; Han Ding; ShaoYang Li; SuYue Zheng; Tao Hong
Journal:  Front Oncol       Date:  2021-07-20       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.